Chirurgia del Fegato a Firenze!

Dal 1° Marzo 2023, Chirurgia del Fegato sarà all'Università di Firenze
AOUC Azienda Ospedaliero-Universitaria Careggi - Largo Brambilla, 3 - 50134 Firenze

Prima serie di ablazioni percutanee per epatocarcinoma

Tito Livraghi, radiologo interventista dell’Ospedale di Vimercate, pubblica la prima serie numericamente consistente di pazienti cirrotici portatori di epatocarcinoma e trattati per via percutanea con alcoolizzazione.

La procedura fu aspramente criticata inizialmente da chirurgi epatobiliari, mentre oggi è diventata lo standard di trattamento per i tumori di diametro fino ai 2 centimetri.

La referenza bibliografica per questo evento è:

Tito Livraghi, Luigi Bolondi, Sergio Lazzaroni, Giuseppe Marin, Alberto Morabito, Gian Ludovico Rapaccini, Andrea Salmi, Guido Torzilli: Percutaneous etharrol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. In: Cancer, vol. 69, no 4, pp. 925 – 929, 1992, ISSN: 0008543X, (Cited by: 402; All Open Access, Bronze Open Access).

Abstract

In 207 cirrhotic patient carriers of hepatocellular carcinoma (HCC), percutaneous ethanol injection (PEI) was administered with ultrasound guidance. The patients were classified as Child's Class A, 136; B, 54; and C, 17. Their mean age was 63.5 years, and the male‐female ratio was 3.5:1. There was a single HCC less than 5 cm in diameter in 162 patients; 45 had more than one HCC. The follow‐up ranged from 5 to 71 months (mean, 25 months). No noteworthy complications occurred during or after 2485 treatments. The 1‐year, 2‐year, and 3‐year survival percentages (by the Kaplan‐Meier method) for the patients with one HCC were 90%, 80%, and 63%, respectively. The corresponding percentages by Child's class were 97%, 92%, and 76% for Class A; 88%, 68%, and 42% for B; and 40%, 0%, and 0% for C. The 1‐year, 2‐year, and 3‐year survival rates for patients with more than one HCC were 90%, 67%, and 31%, respectively. These results were similar to those found by others and showed that PEI was a safe, reproducible, easy‐to‐do, and low‐cost therapeutic technique. In terms of survival, these PEI results were better than the published results of no treatment and equivalent to those of surgery. In uncontrolled series, bias can play an important role. Therefore, additional trials would be useful. Cancer 1992; 69: 925–929. Copyright © 1992 American Cancer Society

manda un messaggio a https://t.me/@ChirurgiaFegato

Invia subito una richiesta con Telegram

Apri direttamente Telegram ed inviaci un SMS veloce e sicuro: riceverai una risposta alla tua necessità in tempi brevissimi

Chirurgia del Fegato all'Università di Firenze!

Chirurgia Epato-Bilio-Pancreatica

AOUC Azienda Ospedaliero-Universitaria Careggi
Largo Brambilla, 3 – 50134 Firenze

Manda una mail a: info@chirurgiadelfegato.it

oppure

Invia un messaggio con Telegram